Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OTLK | Outlook Therapeutics, Inc.

Index	RUT	P/E	-	EPS (ttm)	-0.25	Insider Own	0.80%	Shs Outstand	256.88M	Perf Week	-7.87%
Market Cap	57.69M	Forward P/E	-	EPS next Y	-0.11	Insider Trans	-19.10%	Shs Float	127.42M	Perf Month	-83.44%
Income	-60.30M	PEG	-	EPS next Q	-0.06	Inst Own	10.70%	Short Float / Ratio	20.92% / 4.79	Perf Quarter	-87.89%
Sales	-	P/S	-	EPS this Y	10.60%	Inst Trans	-2.65%	Short Interest	26.66M	Perf Half Y	-79.66%
Book/sh	-0.02	P/B	-	EPS next Y	56.00%	ROA	-127.20%	Target Price	2.50	Perf Year	-83.10%
Cash/sh	0.12	P/C	1.71	EPS next 5Y	-	ROE	-818.70%	52W Range	0.20 - 2.03	Perf YTD	-80.60%
Dividend	-	P/FCF	-	EPS past 5Y	52.80%	ROI	-	52W High	-89.68%	Beta	0.80
Dividend %	-	Quick Ratio	0.90	Sales past 5Y	-	Gross Margin	-	52W Low	4.65%	ATR	0.07
Employees	17	Current Ratio	0.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	21.28	Volatility	5.93% 10.35%
Optionable	No	Debt/Eq	-	EPS Q/Q	-1.20%	Profit Margin	-	Rel Volume	0.61	Prev Close	0.22
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 14 BMO	Payout	-	Avg Volume	5.57M	Price	0.21
Recom	2.50	SMA20	-56.67%	SMA50	-81.93%	SMA200	-82.66%	Volume	3,421,062	Change	-2.74%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$9
May-16-19	Initiated	Oppenheimer	Outperform	$12
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

Show Previous Ratings

Sep-21-23 08:05AM	Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks) -15.08%
Aug-30-23 06:11AM	US FDA declines to approve Outlook Therapeutics' eye disease drug (Reuters) -80.96%
06:00AM	Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
11:47AM	Loading…
Aug-28-23 11:47AM	Outlook Therapeutics (OTLK): A Deep Dive into its Overvalued Status (GuruFocus.com) +10.34%
Aug-14-23 09:55AM	Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings? (Zacks)
08:05AM	Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones (GlobeNewswire)
Aug-01-23 08:45AM	Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-11-23 08:45AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit? (Simply Wall St.)
Jun-06-23 01:59PM	Why Shares of Outlook Therapeutics Rose Tuesday (Motley Fool)
May-15-23 08:05AM	Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Apr-27-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-10-23 11:43AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 37% stake, while 27% is held by private equity firms (Simply Wall St.)
Mar-13-23 07:00AM	Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank (GlobeNewswire)
08:05AM	Loading…
Feb-14-23 08:05AM	Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Feb-07-23 08:05AM	Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-19-23 08:05AM	Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence (GlobeNewswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-09-23 08:05AM	Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire)
Jan-02-23 07:31AM	Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
Dec-29-22 09:05AM	Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire) +5.94%
Dec-23-22 09:00AM	Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note (GlobeNewswire) +21.81%
06:00AM	Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-22-22 08:05AM	Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Dec-01-22 08:05AM	Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference (GlobeNewswire)
Nov-22-22 08:05AM	Outlook Therapeutics® to Present at the BTIG Ophthalmology Day (GlobeNewswire)
Nov-01-22 09:55AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 38% stake, while 25% is held by private equity firms (Simply Wall St.)
Oct-28-22 08:05AM	Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -9.47%
Oct-05-22 06:09AM	Independent Director Kurt Hilzinger Just Bought 33% More Shares In Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
08:05AM	Loading…
Sep-27-22 08:05AM	Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Sep-26-22 08:35AM	Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022 (GlobeNewswire)
Sep-07-22 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-30-22 09:39AM	Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate (Benzinga)
08:05AM	Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire)
Aug-15-22 08:05AM	Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD (GlobeNewswire)
Aug-10-22 08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones (GlobeNewswire)
Aug-04-22 08:05AM	Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference (GlobeNewswire)
Jul-26-22 07:18AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable? (Simply Wall St.)
Jul-05-22 08:05AM	Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note (GlobeNewswire) +7.84%
Jun-14-22 08:05AM	Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010 (GlobeNewswire) +15.95%
May-31-22 08:05AM	Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -31.95%
May-27-22 07:25AM	Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last year (Simply Wall St.) +7.64%
May-18-22 08:05AM	Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.13%
May-13-22 08:05AM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire) +7.38%
May-10-22 08:35AM	Outlook Therapeutics to Participate in Retina World Congress 2022 (GlobeNewswire)
May-09-22 08:35AM	Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight (GlobeNewswire) -7.50%
May-04-22 12:02PM	Here's What Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Apr-22-22 08:05AM	BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics (GlobeNewswire)
Apr-05-22 08:05AM	Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit (GlobeNewswire)
Apr-04-22 07:45PM	Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt? (Simply Wall St.)
Mar-31-22 08:05AM	Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -10.55%
Mar-03-22 08:05AM	Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access (GlobeNewswire) +5.29%
Feb-24-22 08:05AM	Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress (GlobeNewswire) +16.31%
Feb-16-22 10:59AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable? (Simply Wall St.) +7.14%
Feb-14-22 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire)
Feb-10-22 08:05AM	Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-08-22 08:05AM	Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations (GlobeNewswire)
Feb-02-22 05:38PM	KWB Wealth Buys SPDR Portfolio S&P 600 Small Cap ETF, SPDR Portfolio Short Term Corporate ... (GuruFocus.com) -6.71%
08:05AM	Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival (GlobeNewswire)
Jan-25-22 08:05AM	Outlook Therapeutics Provides a Corporate Update and Business Outlook (GlobeNewswire)
Jan-19-22 08:05AM	Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference (GlobeNewswire)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Jan-04-22 08:35AM	Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-22-21 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update (GlobeNewswire)
Dec-15-21 08:05AM	Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia (GlobeNewswire)
Dec-09-21 08:05AM	Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress (GlobeNewswire) -6.29%
Nov-29-21 04:15PM	Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.11%
Nov-24-21 06:49AM	What Type Of Shareholders Make Up Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Share Registry? (Simply Wall St.) -18.59%
Nov-23-21 10:30PM	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million (GlobeNewswire) +5.41%
04:30PM	Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire)
Nov-13-21 11:00AM	Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference (GlobeNewswire)
Nov-10-21 08:05AM	Outlook Therapeutics to Present at the Virtual Investor Roundtable Event (GlobeNewswire)
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th (ACCESSWIRE)
08:05AM	Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference (GlobeNewswire)
Nov-03-21 08:05AM	Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases (GlobeNewswire)
Oct-15-21 08:41AM	11 Best Penny Stocks To Buy According To Hedge Funds (Insider Monkey)
Oct-12-21 12:00PM	Outlook Therapeutics Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab (GlobeNewswire)
Oct-07-21 08:05AM	Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting (GlobeNewswire) +6.70%
Oct-05-21 08:05AM	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire)
Sep-28-21 08:05AM	Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial (GlobeNewswire)
Sep-21-21 08:05AM	Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference (GlobeNewswire)
Sep-13-21 08:05AM	Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference (GlobeNewswire)
Sep-08-21 08:05AM	Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-26-21 09:57AM	Outlook Therapeutics (NASDAQ:OTLK) shareholder returns have been splendid, earning 198% in 1 year (Simply Wall St.)
Aug-13-21 08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update (GlobeNewswire) -5.14%
Aug-11-21 08:05AM	Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Aug-03-21 05:34PM	Why Outlook Therapeutics Stock Surged Today (Motley Fool) +6.64%
07:06AM	Outlook Therapeutics Stock Soars on Positive Results for Eye Treatment (TheStreet.com)
06:00AM	Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Jul-07-21 08:05AM	Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer (GlobeNewswire) +5.79%
Jul-02-21 05:04AM	Does Outlook Therapeutics (NASDAQ:OTLK) Have A Healthy Balance Sheet? (Simply Wall St.)
Jun-14-21 08:05AM	Outlook Therapeutics Announces Inclusion in the Russell 2000® Index (GlobeNewswire)
Jun-08-21 08:05AM	Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial (GlobeNewswire)
May-27-21 08:05AM	Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010 (GlobeNewswire)
May-18-21 06:15AM	How Many Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Do Institutions Own? (Simply Wall St.)
May-14-21 08:05AM	Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update (GlobeNewswire) +7.73%
May-12-21 08:05AM	Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021 (GlobeNewswire)
Mar-31-21 09:23AM	Outlook Therapeutics' Bevacizumab-vikg Shows Favorable Safety Profile In Retinal Disease Study (Benzinga)
08:05AM	Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA (bevacizumab-vikg) (GlobeNewswire)

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dagnon Terry	Chief Operations Officer	Apr 20	Sale	1.14	520,000	590,200	653,058	Apr 21 09:05 PM
Evanson Jeff	Chief Commercial Officer	Jan 20	Sale	1.11	267,000	296,370	745,975	Jan 24 08:08 PM
Evanson Jeff	Chief Commercial Officer	Jan 19	Sale	1.22	103,255	125,971	1,012,975	Jan 19 08:05 PM
Evanson Jeff	Chief Commercial Officer	Jan 18	Sale	1.25	33,738	42,172	1,116,230	Jan 19 08:05 PM
Evanson Jeff	Chief Commercial Officer	Jan 17	Sale	1.31	27,162	35,582	1,149,968	Jan 19 08:05 PM
Sukhtian Faisal Ghiath	Director	Oct 07	Buy	1.29	30,000	38,700	68,000	Oct 11 05:09 PM
Haddadin Yezan Munther	Director	Oct 07	Buy	1.27	3,600	4,572	63,343	Oct 11 05:05 PM
Haddadin Yezan Munther	Director	Oct 06	Buy	1.29	29,743	38,368	59,743	Oct 11 05:05 PM
HILZINGER KURT J	Director	Oct 05	Buy	1.23	15,662	19,264	473,117	Oct 05 04:43 PM
HILZINGER KURT J	Director	Oct 04	Buy	1.29	95,541	123,248	457,455	Oct 05 04:43 PM
HILZINGER KURT J	Director	Oct 03	Buy	1.25	41,798	52,248	361,914	Oct 03 05:19 PM
HILZINGER KURT J	Director	Sep 30	Buy	1.26	33,199	41,831	320,116	Oct 03 05:19 PM
HILZINGER KURT J	Director	Sep 29	Buy	1.19	13,800	16,422	286,917	Oct 03 05:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK | Outlook Therapeutics, Inc.

Upgrade your FINVIZ experience